FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911762019> ?p ?o ?g. }

• W2911762019 endingPage "161" @default.
• W2911762019 startingPage "154" @default.
• W2911762019 abstract "Introduction Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging clinical activity and manageable safety were reported in urothelial carcinoma, non–small-cell lung cancer (NSCLC), hepatocellular carcinoma (HC) and small-cell lung cancer (SCLC) in a multicenter phase I/II study. Safety and clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) were evaluated in the expansion phase. Methods Patients received 10 mg/kg of durvalumab intravenously every 2 weeks for 12 months or until confirmed progressive disease or unacceptable toxicity. The primary objective was safety; clinical activity was a secondary objective. Results Sixty-two patients were enrolled and evaluable (received first dose ≥24 weeks before data cutoff). Median age was 57 years; 40.3% were human papillomavirus (HPV)-positive; 32.3% had tumour cell PD-L1 expression ≥25%, and 62.9% were current/former smokers. They had a median of 2 prior systemic treatments (range, 1–13). All-causality adverse events (AEs) occurred in 98.4%; drug-related AEs occurred in 59.7% and were grade III–IV in 9.7%. There were no drug-related discontinuations or deaths. Objective response rate (blinded independent central review) was 6.5% (15.0% for PD-L1 ≥25%, 2.6% for <25%). Median time to response was 2.7 months (range, 1.2–5.5); median duration was 12.4 months (range, 3.5–20.5+). Median progression-free survival was 1.4 months; median overall survival (OS) was 8.4 months. OS rate was 62% at 6 months and 38% at 12 months (42% for PD-L1 ≥25%, 36% for <25%). Conclusions Durvalumab safety in HNSCC was manageable and consistent with other cohorts of the study. Early, durable responses in these heavily pretreated patients warrant further investigation; phase III monotherapy and combination therapy studies are ongoing. Clinical trial registry clinicaltrials.gov NCT01693562; MedImmune study 1108." @default.
• W2911762019 created "2019-02-21" @default.
• W2911762019 creator A5001771767 @default.
• W2911762019 creator A5008158683 @default.
• W2911762019 creator A5018401879 @default.
• W2911762019 creator A5021550191 @default.
• W2911762019 creator A5022384270 @default.
• W2911762019 creator A5026826195 @default.
• W2911762019 creator A5026861780 @default.
• W2911762019 creator A5028021994 @default.
• W2911762019 creator A5032809504 @default.
• W2911762019 creator A5034168833 @default.
• W2911762019 creator A5041640815 @default.
• W2911762019 creator A5046273815 @default.
• W2911762019 creator A5052140744 @default.
• W2911762019 creator A5052730435 @default.
• W2911762019 creator A5062202820 @default.
• W2911762019 creator A5062235853 @default.
• W2911762019 creator A5062972256 @default.
• W2911762019 creator A5072271778 @default.
• W2911762019 creator A5076873642 @default.
• W2911762019 creator A5090082356 @default.
• W2911762019 date "2019-03-01" @default.
• W2911762019 modified "2023-10-14" @default.
• W2911762019 title "Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort" @default.
• W2911762019 cites W1567007592 @default.
• W2911762019 cites W2014814181 @default.
• W2911762019 cites W2019607817 @default.
• W2911762019 cites W2062312459 @default.
• W2911762019 cites W2101653483 @default.
• W2911762019 cites W2104347254 @default.
• W2911762019 cites W2112951197 @default.
• W2911762019 cites W2122495232 @default.
• W2911762019 cites W2123176392 @default.
• W2911762019 cites W2124427232 @default.
• W2911762019 cites W2126994971 @default.
• W2911762019 cites W2163814058 @default.
• W2911762019 cites W2189285133 @default.
• W2911762019 cites W2468576628 @default.
• W2911762019 cites W2513978049 @default.
• W2911762019 cites W2523194272 @default.
• W2911762019 cites W2529254901 @default.
• W2911762019 cites W2529484692 @default.
• W2911762019 cites W2587327379 @default.
• W2911762019 cites W2599150633 @default.
• W2911762019 cites W2599354912 @default.
• W2911762019 cites W2620740965 @default.
• W2911762019 cites W2780073276 @default.
• W2911762019 cites W2889350033 @default.
• W2911762019 cites W2890365096 @default.
• W2911762019 cites W2890487472 @default.
• W2911762019 doi "https://doi.org/10.1016/j.ejca.2018.12.029" @default.
• W2911762019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30731276" @default.
• W2911762019 hasPublicationYear "2019" @default.
• W2911762019 type Work @default.
• W2911762019 sameAs 2911762019 @default.
• W2911762019 citedByCount "59" @default.
• W2911762019 countsByYear W29117620192019 @default.
• W2911762019 countsByYear W29117620192020 @default.
• W2911762019 countsByYear W29117620192021 @default.
• W2911762019 countsByYear W29117620192022 @default.
• W2911762019 countsByYear W29117620192023 @default.
• W2911762019 crossrefType "journal-article" @default.
• W2911762019 hasAuthorship W2911762019A5001771767 @default.
• W2911762019 hasAuthorship W2911762019A5008158683 @default.
• W2911762019 hasAuthorship W2911762019A5018401879 @default.
• W2911762019 hasAuthorship W2911762019A5021550191 @default.
• W2911762019 hasAuthorship W2911762019A5022384270 @default.
• W2911762019 hasAuthorship W2911762019A5026826195 @default.
• W2911762019 hasAuthorship W2911762019A5026861780 @default.
• W2911762019 hasAuthorship W2911762019A5028021994 @default.
• W2911762019 hasAuthorship W2911762019A5032809504 @default.
• W2911762019 hasAuthorship W2911762019A5034168833 @default.
• W2911762019 hasAuthorship W2911762019A5041640815 @default.
• W2911762019 hasAuthorship W2911762019A5046273815 @default.
• W2911762019 hasAuthorship W2911762019A5052140744 @default.
• W2911762019 hasAuthorship W2911762019A5052730435 @default.
• W2911762019 hasAuthorship W2911762019A5062202820 @default.
• W2911762019 hasAuthorship W2911762019A5062235853 @default.
• W2911762019 hasAuthorship W2911762019A5062972256 @default.
• W2911762019 hasAuthorship W2911762019A5072271778 @default.
• W2911762019 hasAuthorship W2911762019A5076873642 @default.
• W2911762019 hasAuthorship W2911762019A5090082356 @default.
• W2911762019 hasConcept C121608353 @default.
• W2911762019 hasConcept C126322002 @default.
• W2911762019 hasConcept C141071460 @default.
• W2911762019 hasConcept C143998085 @default.
• W2911762019 hasConcept C197934379 @default.
• W2911762019 hasConcept C2776530083 @default.
• W2911762019 hasConcept C2776833033 @default.
• W2911762019 hasConcept C2777546739 @default.
• W2911762019 hasConcept C2777701055 @default.
• W2911762019 hasConcept C2777742743 @default.
• W2911762019 hasConcept C2780030458 @default.
• W2911762019 hasConcept C29730261 @default.
• W2911762019 hasConcept C31760486 @default.
• W2911762019 hasConcept C71924100 @default.
• W2911762019 hasConcept C90924648 @default.

• next